Vernon G. Wong, MD, FACS, is the founder of Icon Bioscience, Inc. Dr. Wong is a pioneer in the field of drug delivery dating back to the early 1970’s. Dr. Wong was the first clinical director of the National Eye Institute and was a tenured Professor at Georgetown University Medical School. He has published over 100 scientific papers. He co-founded and was the core patent holder in Oculex Pharmaceuticals, which was acquired by Allergan Pharmaceuticals for $245 million in 2002.
Chief Executive Officer
William S. (Sandy) White has over 25 years of broad pharmaceutical industry experience, including general management, global corporate development/licensing, R&D and sales/marketing. He previously served as Vice President of R&D/Commercial Development & Planning at Storz Ophthalmics, a division of American Home Products; President/Business Leader of Integrated Protein Technologies, a unit of Monsanto and CEO of BioCache Pharmaceuticals, Inc. He has also served on the boards of BioCache Pharmaceuticals, CropTech Corporation (Chairman), Neumocore Medical Innovations, Inc. and the Virginia Biotechnology Park.
Vice President, Clinical Development
Wendy Yee Murahashi, MD joined IBI in October, 2011 and is responsible for all regulatory and clinical activities. She is an American Academy of Ophthalmology board-certified ophthalmologist with subspecialty training in retina and vitreous. She previously served as Clinical Instructor at the Portland VA Hospital/Casey Eye Institute. Prior to joining IBI, Dr. Murahashi was a Medical Director at Genentech/Roche with clinical trial responsibility involving the Lucentis® program.
Regulatory Affairs Advisor
Stacy N. Suberg, PhD.
Dr. Stacy Suberg has over 25 years of experience in development of products for healthcare. Trained as a neurophysiologist she received her doctorate from the University of California at Davis with an expertise in mechanisms of pain and analgesia. After senior positions in the pharmaceutical industry at Bristol Myers and Searle, Dr. Suberg founded RBR, Ltd, Research Based regulatory for Healthcare. RBR brings together experienced scientists and regulators providing clients with a highly scientific approach to development and approval of healthcare products. Product experience has been across all Divisions of the FDA.
Mr. David Williams has over 25 years of experience in cGMP large and small molecule manufacturing operations, process development/ scale-up, facility design and construction, state and local incentive development programs, and R&D. Prior to TS consulting, he was Senior Vice President of Operations for Chlorogen, Inc., in St. Louis, MO. He joined Chlorogen in June 2003 from CropTech Corporation in Blacksburg, Virginia, where he served as Chief Technology Officer and Sr. VP of Operations. Mr. Williams also served with Monsanto Company as Vice President of Operations for the Integrated Protein Technologies (IPT) business unit; Cephalon, Inc., as Director of Operations; founding partner and VP of Operations for Bio Science Contract Production Corporation (which became Cambrex Bio Science); and North American Vaccine as Director of Manufacturing for pediatric vaccines. Mr. Williams holds a M.S. degree in industrial Microbiology/Biochemistry, and completed PhD. requirements, all but dissertation, in Microbiology/Biochemistry from the University of Oklahoma.